Drug Profile
Research programme: protein tyrosine kinase inhibitor therapeutics - Nexus BioPharma
Alternative Names: Fyn kinase inhibitor therapeutics - Nexus BioPharma; KV-001; NEX-001; Obesity and diabetes therapeutics - Nexus BioPharma; Weight loss drug - Nexus BioPharmaLatest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Nexus BioPharma
- Developer Albert Einstein College of Medicine; Nexus BioPharma
- Class Antidementias; Antihyperglycaemics; Antineoplastics; Obesity therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Proto-oncogene protein c-fyn inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Obesity
- Research Alzheimer's disease; Cancer; Type 2 diabetes mellitus
Most Recent Events
- 04 Sep 2023 Protein tyrosine kinase inhibitor therapeutics are still in early research phase for Alzheimer's disease, Cancer, Type 2 diabetes mellitus in USA (Nexus Biopharma website, Sep 2023)
- 04 Sep 2023 Protein tyrosine kinase inhibitor therapeutics are still in preclinical trials for Obesity in USA (Nexus Biopharma website, Sep 2023)
- 01 Dec 2017 KV 001 licensed to Unknown Company in USA